Anti-inflammatory ApoA-I-mimetic Peptides Bind Oxidized Lipids with Much Higher Affinity Than Human ApoA-I
Overview
Authors
Affiliations
4F is an anti-inflammatory, apolipoprotein A-I (apoA-I)-mimetic peptide that is active in vivo at nanomolar concentrations in the presence of a large molar excess of apoA-I. Physiologic concentrations ( approximately 35 microM) of human apoA-I did not inhibit the production of LDL-induced monocyte chemotactic activity by human aortic endothelial cell cultures, but adding nanomolar concentrations of 4F in the presence of approximately 35 microM apoA-I significantly reduced this inflammatory response. We analyzed lipid binding by surface plasmon resonance. The anti-inflammatory 4F peptide bound oxidized lipids with much higher affinity than did apoA-I. Initially, we examined the binding of PAPC (1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphatidylcholine) and observed that its oxidized products bound 4F with an affinity that was approximately 4-6 orders of magnitude higher than that of apoA-I. This high binding affinity was confirmed in studies with defined lipids and phospholipids. 3F-2 and 3F(14) are also amphipathic alpha-helical octadecapeptides, but 3F-2 inhibits atherosclerosis in mice and 3F(14) does not. Like 4F, 3F-2 also bound oxidized phospholipids with very high affinity, whereas 3F(14) resembled apoA-I. The extraordinary ability of 4F to bind pro-inflammatory oxidized lipids probably accounts for its remarkable anti-inflammatory properties.
Zemski Berry K, Garfield A, Jambal P, Zarini S, Perreault L, Bergman B Diabetologia. 2024; 67(12):2819-2832.
PMID: 39347985 DOI: 10.1007/s00125-024-06280-8.
Emerging Therapeutic Targets for Acute Coronary Syndromes: Novel Advancements and Future Directions.
Mitsis A, Myrianthefs M, Sokratous S, Karmioti G, Kyriakou M, Drakomathioulakis M Biomedicines. 2024; 12(8).
PMID: 39200135 PMC: 11351818. DOI: 10.3390/biomedicines12081670.
Zhen J, Li X, Yu H, Du B J Nanobiotechnology. 2024; 22(1):263.
PMID: 38760755 PMC: 11100215. DOI: 10.1186/s12951-024-02529-x.
Denimal D Antioxidants (Basel). 2024; 13(1).
PMID: 38247481 PMC: 10812436. DOI: 10.3390/antiox13010057.
Zvintzou E, Xepapadaki E, Skroubis G, Mparnia V, Giannatou K, Benabdellah K Pharmaceuticals (Basel). 2023; 16(6).
PMID: 37375802 PMC: 10300751. DOI: 10.3390/ph16060855.